The results of this study found that (i) SREBP-1 upregulation could be induced in 786-O cells amidst visfatin treatment, and this induction could consequently reduce sunitinib’s cytotoxicity to RCC 786-O cells. The gene discussed is NAMPT; the disease is renal cell carcinoma.